

LungLife AI, Inc.
("LungLife" or the "Company")

Block Listing Six Monthly Return

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

Name of applicant:		LungLife AI, Inc.		
Name of scheme:		1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan		
Number and class of securities originally admitted:		1,356,139 common shares of US \$0.0001 each		
Date of admission:		15 November 2021		
Period of return:	From:	15 November 2022	To:	15 May 2023
Balance of unallotted securities under scheme(s) from previous return:		1. 475,583 2. 201,374 3. 673,990		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1. NIL 2. NIL 3. NIL		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		1. NIL 2. NIL 3. NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		1. 475,583 2. 201,374 3. 673,990		
Total number of securities in issue at the end of the period		25,485,982		

Name of contact:	David Anderson, Chief Financial Officer
Telephone number of contact:	+44 (0)20 7933 8780 or lunglifeai@walbrookpr.com

For further information please contact:

LungLife AI, Inc.
Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com
Via Walbrook PR

Investec Bank plc (Nominated Adviser & Broker)
Virginia Bull / Cameron MacRitchie / Lydia
Zychowska

Tel: +44 (0)20 7597 5970

Goodbody (Joint Broker)
Tom Nicholson / Stephen Kane

Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420

Walbrook PR Limited
Alice Woodings / Phillip Marriage

Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Mob: 07407 804 654 / 07867 984 082

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of

lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRGPUMWAUPWGGP